MTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression

Leukemia

Volumn 28, Issue 1, 2014, Pages 203-206

  Guo, F ^a   Li, J ^a   Zhang, S ^a   Du, W ^a   Amarachintha, S ^a   Sipple, J ^a   Phelan, J ^a   Grimes, H L ^a   Zheng, Y ^a   Pang, Q ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; AZD 8055; CISPLATIN; CYTARABINE; ETOPOSIDE; FANCONI ANEMIA GROUP D2 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; FANCONI ANEMIA; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; LETTER; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; HUMANS; LEUKEMIA, T-CELL; TOR SERINE-THREONINE KINASES;

EID: 84891847714     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.215     Document Type: Letter

References (15)

1. Proud CG. The multifaceted role of mTOR in cellular stress responses. DNA Repair (Amst) 2004; 3: 927-934. (Pubitemid 38997934)
2. Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 2010; 285: 14071-14077.
3. Hay N. The Akt-mTOR tango and its relevance to Cancer. Cancer Cell 2005; 8: 179-183. (Pubitemid 41317589)
4. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22. (Pubitemid 47001784)
5. Ciuffreda L, Di Sanza C, Incani UC, Milella M. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets 2010; 10: 484-495.
6. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105: 2527-2534. (Pubitemid 40387055)
7. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 2005; 106: 4261-4268. (Pubitemid 41775935)
8. Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2009; 15: 6732-6739.
9. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009; 69: 6232-6240.
10. Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res 2011; 71: 1573-1583.
11. Kee Y, D'Andrea AD. Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest 2012; 122: 3799-3806.
12. Seif AE. Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. Cancer Genet 2011; 204: 227-244.
13. Hoang B, Benavides A, Shi Y, Yang Y, Frost P, Gera J et al. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. J Biol Chem 2012; 287: 21796-21805.
14. Guo F, Li J, Du W, Zhang S, O'Connor M, Thomas G et al. mTOR regulates DNA damage response through NF-kB-mediated FANCD2 pathway in hematopoietic cells. Leukemia 2013; 27: 2040-2046.
15. Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011; 25: 781-791.